EUVIMEDEUVIMED entdecken
Open Access

Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and Suicidality

Georgios Schoretsanitis, Stefan Weiler, Corrado Barbui, Emanuel Raschi, Chiara Gastaldon

JAMA Network Open · 20.08.2024 · 7 (8) · e2423385

DOI: 10.1001/jamanetworkopen.2024.23385 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 20.08.2024. Verfasst von Georgios Schoretsanitis und 4 weiteren Autor:innen. Beteiligte Einrichtung: The Zucker Hillside Hospital, Department of Psychiatry, Northwell Health, Glen Oaks, New York. Hauptthemen laut MEDLINE: Liraglutide, Glucagon-Like Peptides, World Health Organization, Hypoglycemic Agents. Die Arbeit wurde bisher 113-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have gained use primarily due to their weight-reduction effects, although a regulatory review was undertaken for potential suicidality concern.

Objectives

To evaluate potential signals for suicidal and self-injurious adverse drug reactions (ADRs) associated with the GLP-1 RAs semaglutide and liraglutide. Design, Setting, and Participants Disproportionality analysis through the case-control design using the World Health Organization (WHO) global database of suspected ADRs. Participants were clinical patients worldwide experiencing an ADR suspectedly attributable to semaglutide or liraglutide in the database from inception to August 30, 2023. Data were analyzed from September to December 2023. Exposure Treatment with semaglutide or liraglutide regardless of indication or treatment duration. Main Outcomes and Measures Reporting odds ratio (ROR) and the bayesian information component (IC) with 95% CIs were calculated as measures of disproportionate reporting of suicidal and self-injurious ADRs associated with semaglutide and liraglutide compared with all other medications. Sensitivity analyses were conducted including patients with coreported use of antidepressants and benzodiazepines and using dapagliflozin, metformin, and orlistat as comparators. A disproportionality signal was considered when the lower limits of the ROR and IC were above 1 and 0, respectively.

Results

A total of 107 (median [IQR] age 48 [40-56] years; 59 female patients [55%]) and 162 (median [IQR] age 47 [38-60] years; 100 female patients [61%]) cases of suicidal and/or self-injurious ADRs were reported between November 2000 and August 2023 with semaglutide and liraglutide, respectively. Significant disproportionality was detected only for semaglutide-associated suicidal ideation (ROR, 1.45; 95% CI, 1.18-1.77; IC, 0.53; 95% CI, 0.19-0.78), which remained significant in patients with coreported use of antidepressants (ROR, 4.45; 95% CI, 2.52-7.86; IC, 1.96; 95% CI, 0.98-2.63) and benzodiazepines (ROR, 4.07; 95% CI, 1.69-9.82; IC, 1.67; 95% CI, 0.11-2.65), when compared with dapagliflozin (ROR, 5.56; 95% CI, 3.23-9.60; IC, 0.70; 95% CI, 0.36-0.95), metformin (ROR, 3.86; 95% CI, 2.91-5.12; IC, 1.20; 95% CI, 0.94-1.53) and orlistat (ROR, 4.24; 95% CI, 2.69-6.69; IC, 0.70; 95% CI, 0.36-0.95). Conclusions and Relevance This study using the WHO database found a signal of semaglutide-associated suicidal ideation, which warrants urgent clarification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LiraglutideGlucagon-Like PeptidesWorld Health OrganizationHypoglycemic AgentsSuicideHumansFemaleMaleCase-Control StudiesMiddle AgedAdultSelf-Injurious BehaviorSemaglutide

Substanzen

LiraglutideGlucagon-Like PeptidesHypoglycemic AgentsSemaglutide

Autor:innen und Institutionen

  • The Zucker Hillside Hospital, Department of Psychiatry, Northwell Health, Glen Oaks, New York.
  • Department of Psychiatry, Zucker School of Medicine at Northwell/Hofstra, Hempstead, Glen Oaks, New York.
  • Department of Psychiatry, Psychotherapy and Psychosomatics, Hospital of Psychiatry, University of Zurich, Zurich, Switzerland.
  • Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland.
  • Institute of Primary Care, University of Zurich and University Hospital Zurich, Zurich, Switzerland.
  • WHO Collaborating Centre for Research and Training in Mental Health and Service Evaluation, Department of Neuroscience, Biomedicine and Movement Sciences, Section of Psychiatry, University of Verona, Verona, Italy.

Zitieren

APA

Schoretsanitis, G., Weiler, S., Barbui, C., Raschi, E., & Gastaldon, C. (2024). Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and Suicidality. JAMA Network Open, 7(8), e2423385. https://doi.org/10.1001/jamanetworkopen.2024.23385

Vancouver

Schoretsanitis G, Weiler S, Barbui C, Raschi E, Gastaldon C. Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and Suicidality. JAMA Network Open. 2024;7(8):e2423385. doi:10.1001/jamanetworkopen.2024.23385

BibTeX
@article{Schoretsanitis2024,
  author = {Schoretsanitis, Georgios and Weiler, Stefan and Barbui, Corrado and Raschi, Emanuel and Gastaldon, Chiara},
  title = {Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and Suicidality},
  journal = {JAMA Network Open},
  year = {2024},
  volume = {7},
  number = {8},
  pages = {e2423385},
  doi = {10.1001/jamanetworkopen.2024.23385}
}
Kostenlos starten →